Kerr, KeithBibeau, FrédéricThunnissen, ErikBotling, JohanRyška, AlešWolf, JürgenÖhrling, KatarinaBurdon, PeterMalapelle, UmbertoBüttner, Reinhard2021-11-152021-11-152021-12-01Kerr, K, Bibeau, F, Thunnissen, E, Botling, J, Ryška, A, Wolf, J, Öhrling, K, Burdon, P, Malapelle, U & Büttner, R 2021, 'The evolving landscape of biomarker testing for non-small cell lung cancer in Europe', Lung Cancer, vol. 154, pp. 161-175. https://doi.org/10.1016/j.lungcan.2021.02.0260169-5002https://hdl.handle.net/2164/17493Funding Supported by Amgen (Europe) GmbH (Rotkreuz, Switzerland).155249632engSDG 3 - Good Health and Well-beingprecision medicinepredictive molecular pathologytargeted therapiesNext generation sequencingoncogenic driver mutationsNSCLCR MedicineRJournal item10.1016/j.lungcan.2021.02.026154